SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-307975
Filing Date
2020-12-02
Accepted
2020-12-02 09:37:01
Documents
15
Period of Report
2020-12-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d72793d8k.htm   iXBRL 8-K 27082
2 EX-99.1 d72793dex991.htm EX-99.1 11958
6 GRAPHIC g72793g1202091102600.jpg GRAPHIC 639
7 GRAPHIC g72793img01.jpg GRAPHIC 14208
  Complete submission text file 0001193125-20-307975.txt   192043

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oyst-20201201.xsd EX-101.SCH 3072
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oyst-20201201_lab.xml EX-101.LAB 18887
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oyst-20201201_pre.xml EX-101.PRE 11861
8 EXTRACTED XBRL INSTANCE DOCUMENT d72793d8k_htm.xml XML 3477
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 201362559
SIC: 2836 Biological Products, (No Diagnostic Substances)